A Dark Vector Cognition product

Item 16. Form 10-K Summary

4K characters. Original on sec.gov ·

Item 16. Form 10-K Summary

The 2 tables in Item 16. Form 10-K Summary as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Not applicable.

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Eli Lilly and Company

By/s/ David Ricks
David Ricks
Chair, President, and Chief Executive Officer

February 22, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below on February 22, 2023 by the following persons on behalf of the Registrant and in the capacities indicated.

SignatureTitle
/s/ David RicksChair, President, and Chief Executive Officer (principal executive officer)
DAVID RICKS
/s/ Anat AshkenaziExecutive Vice President and Chief Financial Officer (principal financial officer)
ANAT ASHKENAZI
/s/ Donald ZakrowskiSenior Vice President, Finance, and Chief Accounting Officer (principal accounting officer)
DONALD ZAKROWSKI
/s/ Ralph AlvarezDirector
RALPH ALVAREZ
/s/ Katherine Baicker, Ph.D.Director
KATHERINE BAICKER, Ph.D.
/s/ Erik FyrwaldDirector
ERIK FYRWALD
/s/ Mary Lynne Hedley, Ph.D.Director
MARY LYNNE HEDLEY, Ph. D.
/s/ Jamere JacksonDirector
JAMERE JACKSON
/s/ Kimberly JohnsonDirector
KIMBERLY JOHNSON
/s/ William Kaelin, Jr., M.D.Director
WILLIAM KAELIN, JR., M.D.
/s/ Juan LucianoDirector
JUAN LUCIANO
/s/ Marschall Runge, M.D., Ph.D.Director
MARSCHALL RUNGE, M.D., Ph.D.
/s/ Gabrielle SulzbergerDirector
GABRIELLE SULZBERGER
/s/ Jackson TaiDirector
JACKSON TAI
/s/ Karen WalkerDirector
KAREN WALKER

Trademarks Used In This Report

Trademarks or service marks owned by Eli Lilly and Company or its affiliates, when first used in each item of this report, appear with an initial capital and are followed by the symbol ® or ™, as applicable. In subsequent uses of the marks in the item, the symbols may be omitted.

Byetta® is a trademark of Amylin Pharmaceuticals, Inc.

Glyxambi®, Jardiance®, Jentadueto®, Synjardy®, Trajenta®, and Trijardy® are trademarks of Boehringer Ingelheim International GmbH.

Tyvyt® is a trademark of Innovent Biologics (Suzhou) Co., Ltd.

Previous: Item 15. Exhibits and Financial Statement Schedules